Purchase this article with an account.
DC Kazakos, KG Schmidt, AS Bernd, AG Böhm, LE Pillunat; Ocular Pulse Amplitude in Primary Open Angle Glaucoma Patients on Brimonidine . Invest. Ophthalmol. Vis. Sci. 2002;43(13):845.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Evidence has progressively accumulated over the years to suggest that vascular insufficiency plays an important part in the pathogenesis of glaucomatous optic neuropathy. Thus antiglaucomatous drugs - in addition to reducing intraocular pressure - should not impair perfusion to the optic nerve head, the area of primary damage in this group of multifaceted diseases. This study was designed to evaluate the influence of brimonidine, a potentially vasoconstrictive alpha-2-adrenoceptor agonist, on the ocular pulse amplitude (OPA) in primary open angle glaucoma (POAG) patients. Methods: The influence of standard dosage brimonidine (0.2%, BID, one eye) on OPA (OBF-System, OBF Labs, U.K.), and systemic perfusion parameters was determined in 17 POAG patients. Measurements were taken before and after four weeks of brimonidine therapy. Results: Values represent mean SD. When compared to pretreatment values OPA (2.1 0.1/2.1 0.1 mmHg) and systemic perfusion parameters (RR syst. 142.5 10.2/137.9 9.4 mmHg, RR diast. 87.0 6.0/85.7 6.6 mmHg, heart rate 62.7 6.1/59.3 6.5 min-1) were not significantly (p≷ 0.05) altered following application of brimonidine. Conclusion: A negative effect of brimonidine on OPA in POAG patients was excluded by this study.
This PDF is available to Subscribers Only